The FDA Wants Your Definition of Surgical Autonomy

Nobody has agreed on what it means for a surgical robot to act on its own.
On November 6, 2026, the FDA published a discussion paper that asks the whole field to settle that language first.
The paper covers robots that perform tasks without user intervention and robots controlled by a specialist who is not in the room.
It is not draft or final guidance, and it does not change any rule.
What the FDA Is Actually Asking
The FDA describes the paper as a way to gather early input from manufacturers, clinicians, patients, and the public.
Feedback goes to docket FDA-2026-N-13135 on Regulations.gov by January 5, 2027.
A free hybrid public workshop runs on December 2 and 3, 2026, from 10:00 a.m. to 4:00 p.m. ET each day.
The agenda covers autonomy, remote teleoperation, cybersecurity, risk mitigation, and coverage and reimbursement.
A Definition and a Spectrum
The paper defines autonomy as the ability to perform tasks and make decisions based on current state and sensing, without user intervention.
It separates autonomy from automation, because automation follows predictable rules while autonomy adapts to changing conditions.
The FDA treats autonomy as a spectrum, with the user’s role shifting from performing the task to supervising it.
The paper states that no single framework for levels of autonomy is universally agreed upon.
It calls the six-level scale from Yang and colleagues, published in 2017, the most widely adopted.
As of July 2026, no remotely teleoperated or fully autonomous robotic device has received marketing authorization in the United States.
The Risks the FDA Names
At higher levels of autonomy, device errors may begin and finish before a supervising user can evaluate or interrupt them.
Automation bias, where users defer to the robot over their own judgment, may weaken the human safeguard.
Some users may also lack the expertise to complete a procedure manually if the system fails.
For remote operation, the FDA notes that risk may grow with the distance between the user and the patient.
A remote operator also cannot perceive cues such as the pitch of a bone drill or tissue resistance during palpation.
When a system combines autonomy with remote operation, handoffs between the two modes can create failure modes that neither capability has alone.
What to Watch Next
The workshop sessions will show how manufacturers, hospitals, and payers respond to these questions.
The FDA says the feedback will inform future policy on these devices.
A shared vocabulary for autonomy would make every manufacturer's claim easier to compare and easier to test.
The 2026 Surgical Technology Intelligence Report tracks how the field is changing, and you can read more about it here.


